首页 | 本学科首页   官方微博 | 高级检索  
检索        


Preferred Revascularization Strategies in Patients with Ischemic Heart Failure: A Meta-Analysis
Authors:Jie Xiao  Fen Xu  Chuan-lei Yang  Wei-qiang Chen  Xing Chen  Hua Zhang  Zhan-jie Wei  Jin-ping Liu
Institution:1.Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College,Huazhong University of Science and Technology,Wuhan,China;2.Department of Cardio-Thoracic Surgery,Ganzhou People’s Hospital,Ganzhou,China;3.Department of Cardiovascular Surgery,Central Hospital of Wuhan,Wuhan,China;4.Department of Thyroid Surgery,Central Hospital of Wuhan,Wuhan,China
Abstract:Clinically, coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) is generally used to treat patients with ischemic heart failure. However, the optimal treatment strategy remains unknown. This study examined the efficacy of the two coronary revascularization strategies for severe ischemic heart failure by using a meta-analysis. Studies comparing the efficacy of CABG and PCI were obtained from PubMed, EMBASE, Google Scholar and Cochrane Central Register of Controlled Trials (CENTRAL). The quality of each eligible article was evaluated by Newcastle-Ottawa Quality Assessment Scale (NOS), and the meta-analysis was performed using Stata version 12.0 software. Eventually, 12 studies involving 9248 patients (n=4872 in CABG group; n=4376 in PCI group) were subject to the meta-analysis for subsequent pooling calculation. The pooled hazard ratio (HR) HR=0.83, 95% CI (0.76, 0.90), P<0.001; heterogeneity, P=0.218, I2=22.9%] of CABG compared with that of PCI revealed a statistical superiority of CABG to PCI in terms of the long-term mortality. Furthermore, CABG showed more advantages over PCI with respect to the incidence of myocardial infarction HR=0.51, 95% CI (0.39, 0.67), P<0.001; heterogeneity, P=0.707, I2=0%] and repeat revascularization HR=0.40, 95% CI (0.27, 0.59), P<0.001; heterogeneity, P<0.001, I2=80.1%]. It was concluded that CABG appears to be more advantageous than PCI for the treatment of ischemic heart failure in the given clinical setting.
Keywords:
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号